Search for: "Pharmacia "
Results 101 - 120
of 178
Sorted by Relevance
|
Sort by Date
2 Oct 2008, 6:00 am
I'm sure you are familiar with the old joke about how many lawyers it takes to change a light bulb.So, who were the Pfizer lawyers that were involved in the internal decisions that led to Dr. [read post]
15 Oct 2012, 1:24 am
As discussed here, shareholders first sued Pharmacia and certain of its directors and officers in 2003, alleging that the company had released only part of a long-term clinical study the company had commissioned on the side effects of the drug. [read post]
15 Jul 2014, 11:44 pm
Today I conclude my three-part series on mergers and acquisitions under the Foreign Corrupt Practices Act (FCPA) with a review of the post-acquisition phase. [read post]
18 Feb 2014, 3:18 pm
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
18 Feb 2014, 3:18 pm
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
1 Mar 2010, 12:22 am
Until 1995, many patients combined Premarin, Wyeth's estrogen-based drug, with progestin-laden Provera, made by Pfizer's Pharmacia & Upjohn unit. [read post]
10 Aug 2010, 6:42 pm
Cir. 2008); Pharmacia Corp. v. [read post]
16 Apr 2014, 5:35 am
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Researchers have long suspected a link between testosterone treatment and the risk of heart attack, though millions of men who have been taking the hormonal treatments are just now learning of the… [read post]
18 Feb 2014, 3:18 pm
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
18 Feb 2014, 3:18 pm
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
20 May 2010, 7:30 am
The judge followed the Court of Justice’s interpretation of Article 3(d) in Pharmacia, MIT and Yissum, holding that the authorization required under 3(b) is the first authorisation to place the product on the market as “any” medicinal product. [read post]
21 Nov 2006, 7:40 am
As the CAFC said in Pharmacia v. [read post]
1 Dec 2009, 11:22 am
Pharmacia Corp., [554 F.3d 342, 348]Â (3d Cir. [read post]
17 Apr 2012, 4:30 am
., Pharmacia Corp., and Pfizer, Inc., in the Circuit Court of St. [read post]
6 Aug 2012, 8:08 am
VOL PHARMACIA LTDA. [read post]
25 Jan 2017, 11:25 pm
He notes that the Neurim decision seems to be inconsistent with the CJEU’s decisions in MIT, GSK, Pharmacia and Yissum. [read post]
8 Jun 2013, 10:35 am
Sugen’s appeal against the revocation was fixed for hearing on May 14th 2013 subject to the undertaking given by the appellant (Sugen) that they will not use the revoked patent against the second respondent (Cipla) in other proceedings.According to the appellant (Sugen/Pharmacia) the opposition was not sustainable (second revocation decision) due to the following grounds, which are detailed below:Consideration of Section 25(2) (b):Sugen argued that Section 25(2) (b) should have not… [read post]
19 Dec 2013, 4:56 pm
(Enlarged Board of Appeal in G2/98).Priority can be lost by:narrowing down the disclosure from the priority document in a manner which the invention could not be derived directly and unambiguously from it (Pharmacia Corp v Merck & Co Inc [2002] RPC 41); orwidening or generalizing from the priority disclosure (Beloit Technologies Inc and another v Valmet Paper Machinery Inc and another [1995] RPC 7005 and Unilin)The story continues in Part II. [read post]
7 May 2013, 8:53 am
I do not detect anything in the decisions of the Court of Appeal in Pharmacia and Unilin Beheer which is inconsistent with this approach and in my judgment is one which this court should adopt. [read post]
23 Dec 2018, 4:01 am
The AG refers to CJEU case-law in Yissum and Pharmacia Italia, providing that the definition of the term “product” is independent of the therapeutic use concerned, meaning that an active ingredient or a “combination of active ingredients” remains the same product irrespective of the different therapeutic uses this might have. [read post]
